Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDIONASDAQ:CVKDNASDAQ:GRCENASDAQ:MRNS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDIOCardio Diagnostics$4.09-2.9%$9.30$3.40▼$53.10$7.11M3.791,530 shs28,875 shsCVKDCadrenal Therapeutics$13.34-0.1%$15.81$5.70▼$22.90$26.24M1.4640,167 shs12,753 shsGRCEGrace Therapeutics$2.79-3.8%$2.49$1.75▼$4.97$28.29M0.8956,618 shs13,927 shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.75 million shs260 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDIOCardio Diagnostics-2.85%+3.54%-67.91%-69.66%-80.28%CVKDCadrenal Therapeutics-0.15%-9.56%-18.76%-29.79%+1,333,999,900.00%GRCEGrace Therapeutics-3.79%-6.06%+6.90%-7.92%+278,999,900.00%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-64.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDIOCardio Diagnostics2.9162 of 5 stars3.55.00.00.03.01.70.0CVKDCadrenal Therapeutics2.1406 of 5 stars3.53.00.00.01.01.70.6GRCEGrace Therapeutics2.8755 of 5 stars3.50.00.00.04.20.81.3MRNSMarinus Pharmaceuticals2.4666 of 5 stars3.20.00.04.20.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDIOCardio Diagnostics 3.00Buy$60.001,366.99% UpsideCVKDCadrenal Therapeutics 3.00Buy$32.00139.88% UpsideGRCEGrace Therapeutics 3.00Buy$12.00330.11% UpsideMRNSMarinus Pharmaceuticals 2.40Hold$4.79771.56% UpsideCurrent Analyst Ratings BreakdownLatest CDIO, MRNS, GRCE, and CVKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025CVKDCadrenal TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.005/2/2025GRCEGrace TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDIOCardio Diagnostics$19.90K357.38N/AN/A$0.14 per share29.21CVKDCadrenal TherapeuticsN/AN/AN/AN/A$8.86 per shareN/AGRCEGrace TherapeuticsN/AN/AN/AN/A$5.14 per shareN/AMRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDIOCardio Diagnostics-$8.38MN/A0.00∞N/A-22,732.03%-258.85%-191.20%8/12/2025 (Estimated)CVKDCadrenal Therapeutics-$8.36M-$9.26N/AN/AN/AN/A-142.95%-118.40%8/6/2025 (Estimated)GRCEGrace Therapeutics-$12.85M-$1.16N/AN/AN/AN/A-20.10%-17.10%6/20/2025 (Estimated)MRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)Latest CDIO, MRNS, GRCE, and CVKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/20/2025Q4 2025GRCEGrace Therapeutics-$0.23N/AN/AN/AN/AN/A5/15/2025Q1 2025CDIOCardio Diagnostics-$0.06-$0.97-$0.91-$0.97$0.05 million$0.00 million5/8/2025Q1 2025CVKDCadrenal Therapeutics-$1.64-$2.09-$0.45-$2.09N/AN/A3/13/2025Q4 2024CVKDCadrenal Therapeutics-$1.71-$2.74-$1.03-$2.74N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDIOCardio DiagnosticsN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDIOCardio DiagnosticsN/A8.508.50CVKDCadrenal TherapeuticsN/A3.693.69GRCEGrace TherapeuticsN/A6.066.06MRNSMarinus PharmaceuticalsN/A1.661.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDIOCardio Diagnostics8.06%CVKDCadrenal Therapeutics7.92%GRCEGrace Therapeutics6.08%MRNSMarinus Pharmaceuticals98.80%Insider OwnershipCompanyInsider OwnershipCDIOCardio Diagnostics22.30%CVKDCadrenal Therapeutics48.62%GRCEGrace Therapeutics13.51%MRNSMarinus Pharmaceuticals5.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDIOCardio Diagnostics11.74 million40.52 millionNot OptionableCVKDCadrenal Therapeutics41.97 million916,000Not OptionableGRCEGrace TherapeuticsN/A10.14 million8.77 millionN/AMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionableCDIO, MRNS, GRCE, and CVKD HeadlinesRecent News About These CompaniesStockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)May 21, 2025 | americanbankingnews.comMarinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stockFebruary 11, 2025 | msn.comMarinus Pharmaceuticals director sells shares worth $869January 24, 2025 | msn.comMarinus pharmaceuticals director sells shares for $864January 24, 2025 | msn.comMarinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should KnowJanuary 10, 2025 | zacks.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MRNS, RHE, SSY, CTV on Behalf of ShareholdersJanuary 10, 2025 | stockhouse.comMarinus Pharmaceuticals Inc (MRNS) Stock: Greater Than Its Current Valuation?January 7, 2025 | bovnews.comMARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNSJanuary 6, 2025 | businesswire.comImmedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million DealJanuary 4, 2025 | msn.comMarinus (MRNS) Gets a Hold from Truist FinancialJanuary 4, 2025 | markets.businessinsider.comMarinus Pharmaceuticals Inc (MRNS) Stock: Beyond the Surface of Its Performance?January 4, 2025 | bovnews.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Marinus Pharmaceuticals, Inc. BuyoutJanuary 2, 2025 | markets.businessinsider.comMarinus Pharmaceuticals to be acquired by Immedica for 55c per shareJanuary 1, 2025 | finance.yahoo.comMarinus Pharmaceuticals Inc (MRNS) Stock: Understanding Its Underlying ValueDecember 31, 2024 | bovnews.comMarinus Pharma to Be Acquired by Immedica in $30 Million DealDecember 31, 2024 | marketwatch.comImmedica to buy rare disease drugmaker Marinus for $151 millionDecember 31, 2024 | chicagobusiness.comImmedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.December 31, 2024 | finance.yahoo.comImmedica to buy Marinus Pharmaceuticals, stock rises 4%December 31, 2024 | msn.comMarinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%December 30, 2024 | benzinga.comMRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to ShareholdersDecember 30, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDIO, MRNS, GRCE, and CVKD Company DescriptionsCardio Diagnostics NASDAQ:CDIO$4.09 -0.12 (-2.85%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$4.09 +0.00 (+0.10%) As of 05/30/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.Cadrenal Therapeutics NASDAQ:CVKD$13.34 -0.02 (-0.15%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$14.00 +0.67 (+4.99%) As of 05/30/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Grace Therapeutics NASDAQ:GRCE$2.79 -0.11 (-3.79%) As of 05/30/2025 03:48 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Marinus Pharmaceuticals NASDAQ:MRNS$0.55 0.00 (-0.16%) As of 02/11/2025Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
